


CLAIMS

1. Use of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline, also known as ZD6474:



ZD6474

or a pharmaceutically acceptable salt thereof and one of:

- 10 a) 5-FU;
 b) CPT-11; and
 c) 5-FU and CPT-11

in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.

15

2. Use of ZD6474 or a pharmaceutically acceptable salt thereof and one of:

- a) 5-FU;
 b) CPT-11; and
 c) 5-FU and CPT-11

20 in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human.

3. Use of ZD6474 or a pharmaceutically acceptable salt thereof and one of:

- 25 a) 5-FU;
 b) CPT-11; and
 c) 5-FU and CPT-11

in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human.

4. Use of ZD6474 or a pharmaceutically acceptable salt thereof and 5-FU in the
5 manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
5. Use of ZD6474 or a pharmaceutically acceptable salt thereof and CPT-11 in the
10 manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
6. Use of ZD6474 or a pharmaceutically acceptable salt thereof and 5-FU and CPT-11
in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
15
7. Use according to any one of claims 2, 4, 5 and 6 wherein the cancer is colorectal cancer.
8. A pharmaceutical composition comprising ZD6474 or a pharmaceutically acceptable
20 salt thereof, and 5-FU in association with a pharmaceutically acceptable excipient or carrier.
9. A pharmaceutical composition comprising ZD6474 or a pharmaceutically acceptable salt thereof, and CPT-11 in association with a pharmaceutically acceptable excipient or carrier.
- 25 10. A pharmaceutical composition comprising ZD6474 or a pharmaceutically acceptable salt thereof, and 5-FU and CPT-11 in association with a pharmaceutically acceptable excipient or carrier.
- 30 11. A kit comprising ZD6474 or a pharmaceutically acceptable salt thereof, and 5-FU.
12. A kit comprising ZD6474 or a pharmaceutically acceptable salt thereof, and CPT-11.

13. A kit comprising ZD6474 or a pharmaceutically acceptable salt thereof, and 5-FU and CPT-11.

14. A method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of one of:

- a) 5-FU;
- b) CPT-11; and
- 10 c) 5-FU and CPT-11.